Christopher Kim

Insider Reports History

Location
Hopewell, NJ
Signature
/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Christopher Kim:

Company Role Class Num Shares Value Price $ Report Date Ownership
Apimeds Pharmaceuticals US, Inc. Chairman and CMO, Director Common Stock, par value $0.01 per share 277,500 $485,625 $1.75 16 May 2025 Direct
Apimeds Pharmaceuticals US, Inc. Chairman and CMO, Director Stock Option (right to buy) 3,000 15 Oct 2025 Direct

Insider Reports Filed by Christopher Kim

Symbol Company Period Transactions Value $ Form Type Role Filing Time
APUS Apimeds Pharmaceuticals US, Inc. 15 Oct 2025 1 $0 4 Chairman and CMO, Director 17 Oct 2025, 19:03
APUS Apimeds Pharmaceuticals US, Inc. 16 May 2025 1 $0 4 Chairman and CMO, Director 20 May 2025, 17:00
APUS Apimeds Pharmaceuticals US, Inc. 13 May 2025 2 +$50,359 4 Chairman and CMO, Director 15 May 2025, 18:48
APUS Apimeds Pharmaceuticals US, Inc. 04 Mar 2025 0 $0 3 Chairman and CMO, Director 08 May 2025, 17:06